Merck & Co., Inc. (MRK)
Merck: Buy Opportunity Backed By Growth
Merck: Buy Opportunity Backed By Growth
Merck discontinues development of 2 cancer drugs after trial failures
Merck said on Monday it has discontinued the development of two experimental cancer drugs after their failure in several trials.
CHMP Endorses Merck's Kidney Cancer Drug for Two Indications
The CHMP's opinion is based on positive results from two late-stage studies on MRK's Welireg in two indications associated with renal cell carcinoma.
Merck Has Become Very Cheap Again
Merck's shares have declined, making its dividend yield climb and valuation compress, presenting an attractive investment opportunity at current prices. Keytruda, the company's largest drug, continues to show strong revenue growth and potential for further approvals and market expansion. MRK's diverse drug portfolio, including Gardasil and Winrevair, and its robust pipeline with numerous phase II and III programs support future growth.
Merck (MRK) Ascends While Market Falls: Some Facts to Note
Merck (MRK) reachead $101.25 at the closing of the latest trading day, reflecting a +1.5% change compared to its last close.
Merck (MRK) Stock Sinks As Market Gains: Here's Why
Merck (MRK) closed at $99.75 in the latest trading session, marking a -1.24% move from the prior day.
MRK's Keytruda & Lynparza Combo Meets Goal in Ovarian Cancer Study
The KEYLYNK-001 study evaluating Merck's Keytruda plus chemotherapy followed by maintenance with Lynparza meets the primary goal in epithelial ovarian cancer.
Merck & Co. Inc. (MRK) Citi's 2024 Global Healthcare Conference (Transcript)
Merck & Co. Inc. (NYSE:MRK ) Citi's 2024 Global Healthcare Conference December 5, 2024 8:00 AM ET Company Participants Rob Davis - Chairman and CEO Eliav Barr - Senior VP, Head of Global Clinical Development and CMO Conference Call Participants Geoff Meacham - Citi Geoff Meacham Welcome to the morning session of the First Annual Citi Global Healthcare Conference. My name is Geoff Meacham.
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Merck & Co., Inc. (MRK) 7th Annual Evercore ISI HealthCONx Conference (Transcript)
Merck & Co., Inc. (NYSE:MRK ) 7th Annual Evercore ISI HealthCONx Conference December 3, 2024 1:20 PM ET Company Participants Peter Dannenbaum - SVP, IR Eliav Barr - Chief Medical Officer Conference Call Participants Umer Raffat - Evercore ISI Umer Raffat Okay. Excellent.
Merck Stock Up as Winrevair Meets Goal in Advanced PAH Study
MRK's study of PAH drug Winrevair in a more advanced form of the disease shows overwhelming efficacy.
Why Is Merck Stock Trading Higher On Monday?
On Monday, Merck & Co Inc MRK revealed topline results from the Phase 3 ZENITH study evaluating Winrevair (sotatercept-csrk) in adults with pulmonary arterial hypertension (PAH, WHO Group 1) functional class (FC) III or IV at high risk of mortality.
